Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CARsgen Approved to Launch BMA CAR-T in China for Multiple Myeloma

publication date: Mar 1, 2024

Shanghai’s CARsgen Therapeutics was approved for a China launch of zevorcabtagene autoleucel, its autologous BCMA CAR-T product, in patients with relapsed or refractory multiple myeloma. Patients must have progressed after at least 3 lines of therapy (including a proteasome inhibitor and immunomodulator agent). The approval of zevorcabtagene autoleucel is based on an open-label, single arm, multi-center China Phase II clinical trial. CARsgen is conducting a separate Phase Ib/II trial in North America in the same patient population. The BCMA CAR-T candidate is CARsgen’s first approved product. More details....

Stock Symbol: (HK: 2171)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital